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(95% CI: 0.21, 0.43) and 0.46 (95% CI: 0.37, 0.54) prior to and
after Feb 2010, respectively (P¼ .11). Eighty-six patients
(44%) were considered at high risk for IFI pre-HSCT by
standard criteria. The rate of IFI post HCT was 9/69 (13%)
and 18/127 (14%) prior to and after Feb 2010, respectively.
Proven (n¼2) or probable (n¼2) IFI was only observed in 4
patients (2%), with the remainder having possible IFI.
Subgroup analysis did not ﬁnd any statistical difference
between the two groups for aGVHD analyzed by stem cell
source or IFI analyzed by pre-HSCT risk. In addition, there
was no difference in the number of dose modiﬁcations
required and when patients were analyzed by actual day of
azole start.
Conclusion: Delaying the start of triazole prophylaxis till 7
days after allo-HSCT does not affect outcomes, including
achieving and maintaining therapeutic levels of GVHD
prophylaxis, and incidence of aGVHD or IFI.543
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Cardiac arrhythmias (CA) can be an important complica-
tion of cellular therapy. We performed a retrospective,
single center, comprehensive analysis to understand the
risk factors, outcome and morbidity of cardiac arrhyth-
mias developing in the ﬁrst 100 days after allogeneic
hematopoietic stem cell transplantation in adults. Overall
133 patients received an allogeneic transplant between
01/2008 and 07/2012 and were included in the analysis.
Individuals with pre existing arrhythmias were excluded.
Patients and transplant characteristics are detailed in
Table 1. At least one episode of cardiac arrhythmiaTable 1
Demographics N¼133
Median age (range) 54 (18-70)
Male gender 85 (64%)
Race
African American 25 (19%)
Caucasian 107 (80%)
Other 1 (1%)
Diagnosis
Acute Leukemias 75 (56%)
MDS 20 (15%)
Lymphomas 19 (14%)
CML 11 (8%)
CLL/PLL 5 (4%)
MM 2 (2%)
AA 1 (1%)
Graft source
Adult MUD/MMUD 78 (59%)
Sibling 47 (35%)
Haploidentical family 3 (2%)
Cord blood 5 (4%)
Conditioning
Myeloablative 48 (36%)
RIC/NMA 85 (64%)
Comorbidities
Median left ventricle ejection fraction (range) 60% (33-76)
Hypertension 47 (35%)
Diabetes 26 (20%)
Coronary artery disease 5 (4%)
Smoking history 69 (52%)developed in 25 individuals (18.8%, 95% C.I. 13.0-26.3%)
with 19 individuals developing atrial ﬂutter/ﬁbrillation
and 8 individuals developing AV nodal reentrant tachy-
cardia. Median time of onset of the arrhythmia was 27
days (range 1-96) after transplant. Neither underlying
disease, conditioning regimen, comorbidities, left
ventricular ejection fraction, presence of ventricular dia-
stolic dysfunction, prior use of beta blockers, calcium
channel blockers, ACE inhibitors or ARBs were associated
with higher risk of developing CA in univariate or multi-
variate analysis. Patients who developed CA were older
(median age 56 years) than patients who did not develop
CA (median age 51 years), but this difference was not
statistically signiﬁcant (P ¼ .08). Of the 25 individuals who
developed CA, 13 died prior to day 100 (4 from cardiac
causes). Among the remaining 12 patients, 8 had resto-
ration of sinus rhythm by day 100. Median survival was
14+/- 2 weeks for individuals who developed CA vs. 81 +/-
35 weeks for patients who did not develop CA prior to 100
days (P < .0001). In multivariate analysis, development of
CA prior to 100 days was a strong predictor of mortality
(HR¼2.87, 95% C.I. 1.67-4.95, P ¼ .001) even when adjusted
for age, intensity of the conditioning regimen, comorbid-
ities, chronic medications, left ventricular ejection fraction
and presence of ventricular diastolic dysfunction. We
concluded that the development of CA after allogeneic
transplantation is relatively common, but difﬁcult to
predict on the basis of patient and transplant character-
istics, representing a strong and independent predictor of
post transplant mortality.
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Allogeneic bone marrow transplant (BMT) patients with
cyclosporine-induced hypertension are at risk of serious
complications including intracerebral hemorrhage and
seizures. There is little data describing cyclosporine-
induced hypertension in the allogeneic BMT population.
The aim of this study was to characterize cyclosporine-
induced hypertension in the allogeneic BMT population at
the Medical University of South Carolina (MUSC), while
also investigating what blood pressure (BP) medications
currently used may be most efﬁcacious. We conducted
a single center, IRB approved, retrospective study of
patients receiving an allogeneic BMT from January 1, 2008
to August 31, 2011. Demographic data was collected for all
patients. Those patients experiencing cyclosporine-
induced hypertension had additional data recorded:
number of systolic blood pressure (SBP) readings > 160
mmHG, number of diastolic blood pressure (DBP) readings
>100 mmHg, addition of an antihypertensive medication,
and number of doses and dosage administered. Safety was
assessed through recording number of SBP readings < 100
mmHG, number of DBP readings < 40 mmHg, and the
minimum heart rate (HR) while on cyclosporine. Twenty
seven (27) of 78 patients were identiﬁed as experiencing
